Synthetic Biologics Inc. (AMEX:SYN) does about 621.99K shares in volume on a normal day but saw 3637755 shares change hands in Tuesday trading. The company now has a market cap of 11.86M USD. Its current market price is $0.64, marking a decrease of -0.47% compared to the previous close of $0.64. The 52 week high reached by this stock is $0.75 whilst the lowest price level in 52 weeks is $0.25. The script in recent trading has seen the stock touch a high of $0.68 and a low of $0.60.

Synthetic Biologics Inc. (SYN) has a 20-day trading average at $0.5622 and the current price is -15.27% off the 52-week high compared with 151.98% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.5466 and its 200-day simple moving average is $0.4496. If we look at the stock’s price movements over the week, volatility stands at 10.07%, which decreases to 9.04% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 61.06 to suggest the stock is neutral.

2 analysts observing the Synthetic Biologics Inc. (SYN) stock have set the 12-month price targets for the company’s shares at between $1.25 and $1.50. The median price target is 53.62% away from the current levels at $1.38.

FactSet Research has provided data showing that 2 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on January 06, 2017 when FBR & Co. reiterated the stock to “Outperform” and issued a price target of between $5 and $6. FBR Capital initiated its price target at $10.

The current price level is 13.27%, 16.54%, and 41.70% away from its SMA20, SMA50, and SMA200 respectively, with the SYN price moving below the 50-day SMA on September 01. Synthetic Biologics Inc. (SYN) stock is up 11.71% over the week and 11.49% over the past month. Its price is 25.37% year-to-date and 35.24% over the past year.

The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.18 below consensus estimates by -$0.02. The company’s next earnings report is expected on 11/05/2020, with forecasts estimating quarterly EPS at -$0.17 and -$0.67 for whole year. SYN’s earnings per share are forecast to grow by 28.00% this year and 29.90% over next year.

Its 12-month price target is $1.38. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $1.25, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $1.50.

Outstanding shares total 19.44M with insiders holding 0.13% of the shares and institutional holders owning 8.72% of the company’s common stock. The company has a return on equity of 392.00%. The beta has a value of 1.95.

Bridgeway Ultra Small Company Mar isn’t the only investment manager who changed stakes and is followed by Vanguard Extended Market Index Fu, which sold off 0.0 shares to end up with 18,146 shares worth $10488.0. Fidelity Extended Market Index Fu cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 0.08% position in Synthetic Biologics Inc. thanks to 14928.0 shares amounting to $8628.0.